

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A composition comprising a reduced folate compound and a cobalamin compound in amounts sufficient to exert a chondroprotective effect, wherein said reduced folate is selected from the group consisting of 5-formimino-(6S)-tetrahydrofolic acid and 5-formimino-(6R,S)-tetrahydrofolic acid, wherein the ratio of said reduced folate compound and said cobalamin is 125:1, and wherein said composition further comprises a non-steroidal anti-inflammatory drug (NSAID), a steroid, an immunosuppressant, a cyclooxygenase inhibitor or a combination thereof.
2. (Currently Amended) A composition comprising a reduced folate compound and a cobalamin compound, wherein the ratio of said reduced folate compound and said cobalamin is 125:1, and wherein said composition further comprises a non-steroidal anti-inflammatory drug (NSAID), a steroid, an immunosuppressant, a cyclooxygenase inhibitor or a combination thereof.
3. (Currently Amended) The composition of claim 2, wherein said reduced folate compound is present in an amount from ~~0.01 mg~~ 0.025 mg to 500 mg and said cobalamin compound is present in an amount from 0.0002 mg to ~~10 mg~~ 4.0 mg.
4. (Currently Amended) The composition of claim 2, wherein said reduced folate compound is present in an amount from ~~0.1 mg~~ 0.25 mg to 50 mg and said cobalamin compound is present in an amount from 0.002 mg to ~~1 mg~~ 0.4 mg.
5. (Previously Presented) The composition of claim 2, wherein said composition does not comprise folic acid.
6. (Previously Presented) The composition of claim 2, wherein said composition further comprises a betaine compound.

7. (Original) The composition according to claim 6, wherein said betaine compound is present in amounts of from 500 mg to 20,000 mg.
8. (Original) The composition according to claim 6, wherein said betaine compound is present in amounts of from 500 mg to 2000 mg.
9. (Previously Presented) The composition of claim 2, wherein said reduced folate compound is 5-methyl-tetrahydrofolate.
10. (Previously Presented) The composition of claim 2, wherein said reduced folate is selected from the group consisting of (6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetrahydrofolic acid, (6R,S)-tetrahydrofolic acid, 5-methyl-(6R,S)-tetrahydrofolic acid, 5-formyl-(6R,S)-tetrahydrofolic acid, 10-formyl-(6R,S)-tetrahydrofolic acid, 5,10-methylene-(6SR)-tetrahydrofolic acid, 5,10-methenyl-(6R,S)-tetrahydrofolic acid, and 5-formimino-(6R,S)-tetrahydrofolic acid.
11. (Currently Amended) A composition comprising folic acid or a reduced folate compound, a cobalamin compound, and betaine in amounts sufficient to exert a chondroprotective effect, wherein said folic acid or reduced folate compound comprises 150-1000 mg of said composition, and wherein the ratio of said reduced folate compound and said cobalamin is 125:1, and wherein said composition further comprises a non-steroidal anti-inflammatory drug (NSAID), a steroid, an immunosuppressant, a cyclooxygenase inhibitor or a combination thereof.
12. (Currently Amended) A composition according to claim 11, wherein said cobalamin compound is present in an amount from ~~0.0002 mg~~ 1.2 mg to ~~10 mg~~ 8.0 mg, and said betaine is present in an amounts from 50 mg to 20,0000 mg.

13. (Currently Amended) A composition according to claim 12, wherein said cobalamin compound is present in an amount from ~~0.002 mg~~ 1.2 mg to ~~4 mg~~ 8.0 mg, and said betaine is present in an amount from 500 mg to 2000 mg.

14.-47. (Canceled)

48. (New) The composition of claim 1, wherein said composition further comprises an NSAID selected from aspirin, ibuprofen, ketoprofen, naproxen, diclofenac, and diflunisal.

49. (New) The composition of claim 1, wherein said composition further comprises an NSAID, and wherein said NSAID is not acetaminophen.

51. (New) The composition of claim 1, wherein said composition further comprises an immunosuppressant selected from methotrexate, azathioprine, and cyclophosphamide.

52. (New) The composition of claim 1, wherein said composition further comprises a steroid, and wherein said steroid is a corticosteroid selected from prednisone and methylprednisolone.

53. (New) The composition of claim 1, wherein said composition further comprises a cyclooxygenase inhibitor, and wherein said cyclooxygenase inhibitor is rofecoxib.

54. (New) The composition of claim 2, wherein said composition further comprises an NSAID selected from aspirin, ibuprofen, ketoprofen, naproxen, diclofenac, and diflunisal.

55. (New) The composition of claim 2, wherein said composition further comprises an NSAID, and wherein said NSAID is not acetaminophen.

56. (New) The composition of claim 2, wherein said composition further comprises an immunosuppressant selected from methotrexate, azathioprine, and cyclophosphamide.

57. (New) The composition of claim 2, wherein said composition further comprises a steroid, and wherein said steroid is a corticosteroid selected from prednisone and methylprednisolone.

58. (New) The composition of claim 2, wherein said composition further comprises a cyclooxygenase inhibitor, and wherein said cyclooxygenase inhibitor is rofecoxib.

59. (New) The composition of claim 11, wherein said composition further comprises an NSAID selected from aspirin, ibuprofen, ketoprofen, naproxen, diclofenac, and diflunisal.

60. (New) The composition of claim 11, wherein said composition further comprises an NSAID, and wherein said NSAID is not acetaminophen.

61. (New) The composition of claim 11, wherein said composition further comprises an immunosuppressant selected from methotrexate, azathioprine, and cyclophosphamide.

62. (New) The composition of claim 11, wherein said composition further comprises a steroid, and wherein said steroid is a corticosteroid selected from prednisone and methylprednisolone.

63. (New) The composition of claim 11, wherein said composition further comprises a cyclooxygenase inhibitor, and wherein said cyclooxygenase inhibitor is rofecoxib.

64. (New) A composition comprising a reduced folate compound and a cobalamin compound, wherein said composition further comprises a non-steroidal anti-inflammatory drug (NSAID), a steroid, an immunosuppressant, a cyclooxygenase inhibitor or a combination thereof.

65. (Previously Presented) The composition of claim 64, wherein said reduced folate compound is 5-methyl-tetrahydrofolate.

66. (Previously Presented) The composition of claim 64, wherein said reduced folate is selected from the group consisting of (6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetrahydrofolic acid, (6R,S)-tetrahydrofolic acid, 5-methyl-(6R,S)-tetrahydrofolic acid, 5-formyl-

(6R,S)-tetrahydrofolic acid, 10-formyl-(6R,S)-tetrahydrofolic acid, 5,10-methylene-(6SR)-tetrahydrofolic acid, 5,10-methenyl-(6R,S)-tetrahydrofolic acid, and 5-formimino-(6R,S)-tetrahydrofolic acid.

67. (New) The composition of claim 64, wherein said composition further comprises an NSAID selected from aspirin, ibuprofen, ketoprofen, naproxen, diclofenac, and diflunisal.

68. (New) The composition of claim 64, wherein said composition further comprises an NSAID, and wherein said NSAID is not acetaminophen.

69. (New) The composition of claim 64, wherein said composition further comprises an immunosuppressant selected from methotrexate, azathioprine, and cyclophosphamide.

70. (New) The composition of claim 64, wherein said composition further comprises a steroid, and wherein said steroid is a corticosteroid selected from prednisone and methylprednisolone.

71. (New) The composition of claim 64, wherein said composition further comprises a cyclooxygenase inhibitor, and wherein said cyclooxygenase inhibitor is rofecoxib.